Fairmount Funds Management LLC Bei Gene, Ltd. Transaction History

Fairmount Funds Management LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$125.51 - $229.3 $19.2 Million - $35.1 Million	153,043 Added 177.13%	239,443 $52.7 Million
Q3 2022 Nov 09, 2022	SELL	$131.8 - $202.24 $3.3 Million - $5.06 Million	-25,000 Reduced 22.44%	86,400 $11.6 Million
Q2 2022 Aug 15, 2022	BUY	$121.11 - $216.05 $13.5 Million - $24.1 Million	111,400 New	111,400 $18 Million

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.9B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Fairmount Funds Management LLC, based on Form 13F filings with the SEC.

Stay updated on Fairmount Funds Management LLC with notifications on news.